At ImmunoPreCept, the focus is on identifying factors that promote health and those that contribute to illness. To uncover hidden signals, research examines the body’s earliest changes before symptoms appear. With an emphasis on the immune system, the cluster aims to anticipate, halt, and intercept disease using state-of-the-art technologies. The overarching goal is to shift medicine toward long-term health, resilience, and prevention.
ImmunoPreCept pursues a comprehensive reseearch program with three interconnected areas, each focussing on different parts of health-disease trajectories.
Which molecular and cellular processes operate in the earliest stages to preserve health, and in what ways can activating these mechanisms strengthen the body’s resilience to environmental and physiological stressors over time?
How can we detect the earliest signs of deviation from healthy development after exposure to stressors, particularly in the immune system, and use these indicators to predict disease progression, identify biomarkers, and understand why some individuals have especially robust immune responses?
How does the body restore health after therapeutic intervention, and which biological and immunological processes characterize remission states in which disease activity is controlled but complete recovery and full functional health have not yet been achieved?
ImmunoPreCept’s research focuses on applying knowledge to practical problems rather than just academic discoveries. Our Bridging Programs are intended to link clinical applications, public health efforts, and fundamental scientific research. To guarantee that our discoveries are converted into workable solutions for illness prevention and health promotion, these initiatives bring together researchers, physicians, legislators, and business specialists.
How can technological innovation and AI-driven diagnostics be transformed into early, preventive treatments for patients?
How can meaningful public involvement shape early intervention, prevention research, and health policy?
